Related Experiment Videos

PIK3CA somatic mutations in breast cancer: Mechanistic insights from Langevin dynamics simulations

Parminder K Mankoo1, Saraswati Sukumar, Rachel Karchin

  • 1Department of Biomedical Engineering and Institute for Computational Medicine, Johns Hopkins University, Baltimore, Maryland 21218, USA.

Proteins
|October 28, 2008
PubMed

Insights

Somatic mutations in PIK3CA drive cancer by altering its structure and function. Computational studies reveal how specific PIK3CA mutations enhance substrate access and activity, suggesting targeted inhibitor development for PIK3CA-driven cancers.

Area of Science:

  • Molecular Biology
  • Cancer Genetics
  • Structural Biology

Background:

  • Somatic mutations in PIK3CA are prevalent in various human cancers, including breast cancer.
  • Most PIK3CA mutations lead to increased kinase activity and are linked to oncogenesis.
  • The precise mechanisms by which these mutations drive tumor development remain incompletely understood.

Purpose of the Study:

  • To investigate the structural and dynamic consequences of recurrent PIK3CA mutations.
  • To elucidate the molecular mechanisms underlying PIK3CA-mediated oncogenicity.
  • To explore the potential for developing structure-based, mutant-specific inhibitors.

Main Methods:

  • Computational structural studies using homology modeling of wildtype and mutant PIK3CA.
  • Analysis of molecular dynamics simulations to assess structural changes and protein behavior.
  • Examination of mutations at specific hotspots within the kinase and helical domains.

Main Results:

  • H1047R/L PIK3CA mutants showed an enlarged catalytic cleft, potentially facilitating substrate entry and increasing turnover.
  • Mutant H1047R/L exhibited enhanced activation loop mobility compared to wildtype PIK3CA.
  • The P539R mutant displayed increased hydrogen bond and salt-bridge interactions, suggesting enhanced thermostability.

Conclusions:

  • Mutant-specific alterations in the catalytic cleft and activation loop dynamics provide mechanistic insights into PIK3CA oncogenicity.
  • These findings support the development of targeted therapies for PIK3CA-mutated cancers.
  • Structure-based drug design can yield mutant-specific inhibitors for PIK3CA-positive breast cancers.

Related Concept Videos

Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...